Recent developments in steroidal and nonsteroidal aromatase inhibitors for the chemoprevention of estrogen-dependent breast cancer

European Journal of Medicinal Chemistry

Volumn 102, Issue , 2015, Pages 375-386

  Ahmad, Irshad ^a   Shagufta, ^a  

^a AMERICAN UNIVERSITY OF RAS AL KHAIMAH   (United Arab Emirates)

Author keywords

Aromatase; Breast cancer; Nonsteroidal aromatase inhibitors; Steroidal aromatase inhibitors

Indexed keywords

16 [3 [3 (IMIDAZOLE 1 YL)PROPOXY]BENZYLIDENE] 4 ANDROSTENE 3,17 DIONE; 16 [4 [3 (IMIDAZOL 1 YL)PROPOXY] 3 METHOXYBENZYLIDENE] 5 ANDROSTENE 3BETA,17BETA DIOL; 16BETA (IMIDAZOL 1 YL) 4 ANDROSTA 1,4 DIENE 3,17 DIONE; 16BETA (IMIDAZOL 1 YL) 4 ANDROSTENE 3,17 DIONE; ANASTROZOLE; ANTINEOPLASTIC AGENT; APIGENIN; AROMATASE; AROMATASE INHIBITOR; ATAMESTANE; BIOCCHANIN A; CHRYSIN; ESTROGEN; EXEMESTANE; FORMESTANE; LETROZOLE; LIAROZOLE; PLOMESTANE; QUERCETIN; RESVERATROL; STEROID; UNCLASSIFIED DRUG; VOROZOLE;

ARTICLE; BREAST CANCER; CANCER PREVENTION; DRUG STRUCTURE; ENANTIOMER; ENZYME INHIBITION; NONHUMAN; BREAST NEOPLASMS; CHEMISTRY; CONFORMATION; DRUG DESIGN; FEMALE; HUMAN; METABOLISM; STRUCTURE ACTIVITY RELATION; SYNTHESIS;

ANTINEOPLASTIC AGENTS; AROMATASE; AROMATASE INHIBITORS; BREAST NEOPLASMS; DRUG DESIGN; ESTROGENS; FEMALE; HUMANS; MOLECULAR CONFORMATION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84939810868     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2015.08.010     Document Type: Short Survey

References (94)

1. American Cancer Society, Cancer Facts and Figures, 2015. http://www.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2015/index.
2. J. Gray, N. Evans, B. Taylor, L. Rizzo, M. Walker, State of the evidence: the connection between breast cancer and the environment, Int. J. Occup. Environ. Health 15 (1) (2009) 43-78.
3. R.W. Brueggemeier, J.A. Richards, S. Joomprabutra, A.S. Bhat, J.L. Whetstone, Molecular pharmacology of aromatase and its regulation by endogenous and exogenous agents, J. Steroid Biochem. Mol. Biol. 79 (1-5) (2001) 75-84.
4. (a) W.C. Park, V.C. Jordan, Selective estrogen receptor modulators (SERMS) and their roles in breast cancer prevention, Trends Mol. Med. 8 (2) (2002) 82-88;
5. (b) D.J. Nelson, Shagufta, R. Kumar, Characterization of a tamoxifen-tethered single-walled carbon nanotube conjugate by using NMR spectroscopy, Anal. Bioanal. Chem. 404 (2012) 771-776;
6. (c) Shagufta, A.K. Srivastava, R. Sharma, R. Mishra, A.K. Balapure, P.S.R. Murthy, G. Panda, Substituted phenanthrenes with basic amino side chains: a new series of anti-breast cancer agents, Bioorg. Med. Chem. 14 (2006) 1497-1505.
7. W.R. Miller, Biological rationale for endocrine therapy in breast cancer, Best. Pract. Res. Clin. Endocrinol. Metab. 18 (1) (2004) 1-32.
8. M. Recanatini, A. Cavalli, P. Valenti, Nonsteroidal aromatase inhibitors: recent advances, Med. Res. Rev. 22 (3) (2002) 282-304.
9. N. Murthy, A.R. Rao, G.N. Sastry, Aromatase inhibitors: a new paradigm in breast cancer, Curr. Med. Chem. Anticancer Agents 4 (2004) 523-535.
10. Y. Mouftuoglu, G. Mustata, Pharmacophore modeling strategies for the development of novel nonsteroidal inhibitors of human aromatase (CYP19), Bioorg. Med. Chem. Lett. 20 (10) (2010) 3050-3064.
11. K. Mokbel, The evolving role of aromatase inhibitors in breast cancer 7 (5) (2002) 279-283.
12. A. Maiti, M. Cuendet, V.L. Croy, D.C. Endringer, G.M. Pezzuto, M. Cushman, Synthesis and biological evaluation of (+/-)an-abyssinone II and its analogues as aromatase inhibitors for chemoprevention of breast cancer, J. Med. Chem. 50 (2007) 2799-2806.
13. J.R. Benson, O. Ravisekar, Aromatase inhibitors for the treatment of breast cancer, Curr. Cancer Ther. Rev. 3 (2007) 67-79.
14. S. Barker, Non-steroidal anti-estrogens in the treatment of breast cancer, Curr. Opin. Investig. Drugs 7 (12) (2006) 1085-1091.
15. M.J. Balunas, B. Su, R.W. Brueggemeier, A.D. Kinghorn, Natural products as aromatase inhibitors, Anticancer Agents Med. Chem. 8 (6) (2008) 646-682.
16. I.E. Smith, M. Dowsett, Aromatase inhibitors in breast cancer, N. Eng. J. Med. 348 (24) (2003) 2431-2442.
17. E.R. Simpson, M. Dowsett, Aromatase and its inhibitors: significance for breast cancer therapy, Recent Prog. Horm. Res. 57 (2002) 317-338.
18. G.J. Sabnis, D. Jevolac, B. Lomg, A. Brodie, The role of growth factor receptor pathways in human breast cancer cells adapted to long-term estrogen deprivation, Cancer Res. 65 (9) (2005) 3903-3910.
19. R.J. Santen, E.K. Lobenhofer, C.A. Afshari, Y. Bao, R.X. Song, Adaptation of estrogen-regulated genes in long-term estradiol deprived MCF-7 breast cancer cells, Breast Cancer Res. Treat. 94 (3) (2005) 213-223.
20. A.M. Brodie, W.C. Schwarzel, A.A. Shaikh, H.J. Brodie, The effect of an aromatase inhibitor 4-hydroxy-4-androstene-3,17-dione, on estrogen-dependent processes in reproduction and breast cancer, Endocrinology 100 (6) (1977) 1684-1695.
21. F. Buzzetti, E.D. Salle, A. Longo, G. Briatico, Synthesis and aromatase inhibition by potential metabolites of exemestane (6-methylenandrosta-1,4-diene-3,17-dione), Steroids 58 (11) (1993) 527-532.
22. D. Henderson, G. Norbisrath, U. Kerb, 1-Methyl-1,4-androstadiene-3,17-dione (SH 489): characterization of an irreversible inhibitor of estrogen biosynthesis, J. Steroid Biochem. 24 (1) (1986) 303-306.
23. J.O. Johnston, Biological characterization of 10-(2-propynyl)estr-4-ene-3,17 dione (MDL 18,962), an enzyme-activated inhibitors of aromatase, Steroids 50 (1987) 105-120.
24. K.M.P. Gasi, S.M. Stankovic, J.J. Csanadi, E.A. Djurendic, M.N. Sakac, L.M. Mijacevic, O.N. Arcson, S.Z. Stojanovic, S. Andric, D.M. Gabor, R. Kovacevic, New D-modified androstane derivatives as aromatase inhibitors, Steroids 66 (2001) 645-653.
25. K.M.P. Gasi, D.A. Miljkovic, L.D.M. Mijacevic, E.A. Djurendic, S.Z. Stojanovic, M.N. Sakac, M.D. Djurendic, S.M. Stankovic, D. Lazar, S. Andric, R. Kovacevic, Synthesis, X-ray crystal structures and biological activity of 16-amino-17-substituted-D-homo steroid derivatives, Steroids 68 (2003) 667-676.
26. K.M.P. Gasi, S.Z. Stojanovic, M.N. Sakac, M. Popsavin, S.J. Santa, S.M. Stankovic, O.R. Klisuric, N. Andric, R. Kovacevic, Synthesis and anti-aromatase activity of some new steroidal D-lactones, Steroids 70 (2005) 47-53.
27. E.A. Djurendic, M.N. Sakac, M.P. Zavis, A.R. Gakovic, J.J. Canadi, S.A. Andric, O.R. Klisuric, V.V. Kojic, G.M. Bogdanovic, K.M.P. Gasi, Synthesis and biological evaluation of some new A,B-ring modified steroidal D-lactones, Steroids 73 (2008) 681-688.
28. K.M.P. Gasi, M.D.D. Brenesel, E.A. Djurendic, M.N. Sakac, J.J. Canadi, J.J. Daljev, T. Armbruster, S. Andric, D.M. Sladic, T.T. Bozic, I.T. Novakovic, Z.D. Juranic, Synthesis and biological evaluation of some 17-picolyl and 17-picolinylidene androst-5-ene derivatives, Steroids 72 (2007) 31-40.
29. M. Sakac, A. Gakovic, S. Stojanovic, E. Djurendic, V. Kojic, G. Bogdanovic, K.P. Gasi, Synthesis and biological evaluation of a series of A,B-ring modified 16,17-secoandrostane derivatives, Bioorg. Chem. 36 (2008) 128-132.
30. E. Djurendic, J. Daljev, M. Sakac, J. Canadi, S.J. Santa, S. Andric, O. Klisuric, V. Kojic, G. Bogdanovic, M.D. Brenesel, S. Novakovic, K.P. Gasi, Synthesis of some epoxy and/or N-oxy 17-picolyl and 17-picolinylidene-androst-5-ene derivatives and evaluation of their biological activity, Steroids 73 (2008) 129-138.
31. R. Bansal, S. Guleria, S. Thota, R.W. Hartmann, C. Zimmer, Synthesis and biological evaluation of 16E-arylidenosteroids as cytotoxic and anti-aromatase agents, Chem. Pharm. Bull. 59 (3) (2011) 327-331.
32. R. Bansal, S. Thota, N. Karkra, M. Minu, C. Zimmer, R.W. Hartmann, Synthesis and aromatase inhibitory activity of some new 16E-arylidenosteroids, Bioorg. Chem. 45 (2012) 36-40.
33. R. Bansal, S. Guleria, S. Thota, S.L. Bodhankar, M.R. Patwardhan, C. Zimmer, R.W. Hartmann, A.L. Harvey, Design, synthesis and evaluation of novel 16-imidazolyl substituted steroidal derivatives possessing potent diversified pharmacological properties, Steroids 77 (2012) 621-629.
34. R. Bansal, S. Guleria, S. Thota, R.W. Hartmann, C. Zimmer, Synthesis of imidazole-derived steroidal hybrids as potent aromatase inhibitors, Med. Chem. Res. 22 (2013) 692-698.
35. M.R. Yadav, P.M. Sabale, R. Giridhar, C. Zimmer, J. Haupenthal, R.W. Hartmann, Synthesis of some novel androstanes as potential aromatase inhibitors, Steroids 76 (2011) 464-470.
36. M.R. Yadav, P.M. Sabale, R. Giridhar, C. Zimmer, R.W. Hartmann, Steroidal cabonitriles as potential aromatase inhibitors, Steroids 77 (2012) 850-857.
37. M. Numazawa, W. Handa, C. Hasegawa, M. Takahashi, Structure-activity relationships of 2α-substituted androstenedione analogues as aromatase inhibitors and their aromatization reactions, J. Steroid Biochem. Mol. Biol. 97 (2005) 353-359.
38. M. Numazawa, S. Komatsu, T. Tominaga, K. Yamashita, Structure-activity relationships of estrogen derivatives as aromatase inhibitors. Effect of heterocyclic substituents, Chem. Pharm. Bull. 56 (9) (2008) 1304-1309.
39. S. Komatsu, A. Yaguchi, K. Yamashita, M. Nagaoka, M. Numazawa, 6b,19-Bridged androstenedione analogs as aromatase inhibitors, Steroids 74 (2009) 884-889.
40. C.L. Varela, C. Amaral, G. Correia-da-Silva, R.A. Carvalho, N.A. Teixeira, S.C. Costa, M.F. Roleira, E.J. Tavares-da-Silva, Design, synthesis and biochemical studies of new 7a-allylandrostanes as aromatase inhibitors, Steroids 78 (2013) 662-669.
41. M.M.D.S. Cepa, E.J. Tavares da Silva, G. Correia-da-Silva, F.M.F. Roleira, N.A.A. Teixeira, Synthesis and biochemical studies of 17-substituted androst-3-enes and 3,4-epoxyandrostanes as aromatase inhibitors, Steroids 73 (2008) 1409-1415.
42. 19 steroidal 17-oxime analogs, Molecules 16 (2011) 9868-9885.
43. D. Ghosh, J. Lo, D. Morton, D. Valette, J. Xi, J. Griswold, S. Hubbell, C. Egbuta, W. Jiang, J. An, H.M.L. Davies, Novel aromatase inhibitors by structure-guided design, J. Med. Chem. 55 (19) (2012) 8464-8476.
44. V.C.O. Njar, A.M.H. Brodie, Comprehensive pharmacology and clinical efficacy of aromatase inhibitors, Drugs 58 (2) (1999) 233-255.
45. K. Hajela, A.K. Jha, J. Pandey, Non steroidal estrogen antagonists: current status and future perspectives, Curr. Med. Chem. Immunol. Endocr. Metab. Agents 1 (2001) 235-256.
46. A.U. Buzdar, R. Chlebowski, J. Cuzick, S. Duffy, J. Forbes, W. Jonat, P. Ravdin, Defining the role of aromatase inhibitors in the adjuvant endocrine treatment of early breast cancer, Curr. Med. Res. Opin. 22 (8) (2006) 1575-1585.
47. R.W. Brueggemeier, Update on the use of aromatase inhibitors in breast cancer, Expert Opin. Pharmacother. 7 (14) (2006) 1919-1930.
48. M. Baum, A. Buzdar, The current status of aromatase inhibitors in the management of breast cancer, Surg. Clin. North Am. 83 (4) (2003) 973-994.
49. W. Gradishar, Landmark trials in endocrine adjuvant therapy for breast carcinoma, Cancer 106 (5) (2006) 975-981.
50. A. Brodie, Aromatase inhibitors in breast cancer, Trends Endocrinol. Metab. 13 (2) (2002) 61-65.
51. C.D. Jones, M.A. Winter, K.S. Hirsch, N. Stamm, H.M. Taylor, H.E. Holden, J.D. Davenport, E.V. Krumkalns, R.G. Suhr, Estrogen synthetase inhibitors. 2. Comparison of the in vitro aromatase inhibitory activity for a variety of nitrogen heterocycles substituted with diarylmethane or diarylmethanol groups, J. Med. Chem. 33 (1) (1990) 416-429.
52. M. Okada, T. Yoden, E. Kawaminami, Y. Shimada, M. Kudoh, Y. Isomura, H. Shikama, T. Fujikura, Studies on aromatase inhibitors. I. Synthesis and biological evaluation of 4-amino-4H-1,2,4-triazole derivatives, Chem. Pharm. Bull. 44 (10) (1996) 1871-1879.
53. M. Murthy, A.R. Rao, G.N. Sastry, Aromatase inhibitors: a new paradigm in breast cancer, Curr. Med. Chem. Anticancer Agents 4 (2004) 523-535.
54. E.R. Simpson, M.S. Mahendroo, G.D. Means, M.W. Kilgore, C.J. Corbin, C.R. Mendelson, Tissue-specific promoters regulate aromatase cytochrome P450 expression, J. Steroid Biochem. Mol. Biol. 44 (1993) 321-330.
55. H. Bayer, C. Batzl, R.W. Hartmann, A. Mannschreck, New aromatase inhibitors. Synthesis and biological activity of pyridyl-substituted tetralone derivatives, J. Med. Chem. 34 (9) (1991) 2685-2691.
56. R.W. Hartmann, H. Bayer, G. Grun, Aromatase inhibitors. Syntheses and structure-activity studies of novel pyridyl-substituted indanones, indans, and tetralins, J. Med. Chem. 37 (9) (1994) 1275-1281.
57. G.A. Wachter, R.W. Hartmann, T. Sergejew, G.L. Grun, D. Ledergerber, Tetrahydro-naphthalenes: influence of heterocyclic substituents on inhibition of steroidogenic enzymes P450 arom and P450 17, J. Med. Chem. 39 (1996) 834-841.
58. P. Auvray, S. Moslemi, P. Sourdaine, S. Galopin, G.-E. Seralini, C. Enguehard, P. Dallemagne, R. Bureau, P. Sonnet, S. Rault, Evidence for new potent nonsteroidal human aromatase inhibitor and comparison with equine aromatase inhibition for understanding of the mammalian active site, Eur. J. Med. Chem. 33 (1998) 451-462.
59. R.W. Hartmann, H. Bayer, G. Grun, T. Sergejew, U. Bartz, M. Mitrenga, Pyridyl-substituted tetrahydrocyclopropa[a]naphthalenes: highly active and selective inhibitors of P450 arom, J. Med. Chem. 38 (1995) 2103-2111.
60. C. Jacobs, M. Frotscher, G. Dannhardt, R.W. Hartmann, 1-Imidazolyl (alkyl) substituted di and tetrahydroquinolines and analogs. Synthesis and evaluation of dual inhibitors of P450 TxA 2 and P450 arom, J. Med. Chem. 43 (2000) 1841-1851.
61. M. Le Borgne, P. Marchand, B. Delevoye-Seiller, J.M. Robert, G. Le Baut, R.W. Hartmann, M. Palzer, New selective nonsteroidal aromatase inhibitors: synthesis and inhibitory activity of 2,3 or 5-(a-azolybenzyl)-1H-indoles, Bioorg. Med. Chem. Lett. 9 (1999) 333-336.
62. M.P. Leze, M.L. Borgne, P. Pinson, A. Palusczak, M. Duflos, G.L. Baut, R.W. Hartmann, Synthesis and biological evaluation of 5-[(aryl)(1H-imidazol- 1-yl)methyl]-1H-indoles: potent and selective aromatase inhibitors, Bioorg. Med. Chem. Lett. 16 (2006) 1134-1137.
63. M.P. Leze, A. Palusczak, R.W. Hartmann, M.L. Borgne, Synthesis of 6- and 4-functionalized indoles via a reductive cyclization approach and evaluation as aromatase inhibitors, Bioorg. Med. Chem. Lett. 18 (2008) 4713-4715.
64. R. Wang, H.-F. Shi, J.-F. Zhao, Y.-P. He, H.-B. Zhang, J.-P. Liu, Design, synthesis and aromatase inhibitory activities of novel indole-imidazole derivatives, Bioorg. Med. Chem. Lett. 23 (2013) 1760-1762.
65. R. Whomsley, E. Fernandez, P.J. Nicholls, H.J. Smith, P. Lombardi, V. Pestellini, Substituted 1-[benzofuran-2-yl)-phenylmethyl]-imidazoles as potent inhibitors of aromatase in vitro and in female rats in vivo, J. Steroid Biochem. Mol. Biol. 44 (4-6) (1993) 675-676.
66. C.P. Owen, P.J. Nicholls, H.J. Smith, R. Whomsley, Inhibition of aromatase (P450Arom) by some 1-(benzofuran-2-ylmethyl)imidazoles, J. Pharm. Pharmacol. 51 (4) (1999) 427-433.
67. G.A. Khodarahmi, H.J. Smith, P.J. Nicholls, M. Ahmadi, Medicinal chemistry: enantioselectivity of some 1-(benzofuran-2-yl)-1-(1-H-imidazol-1-yl) alkanes as inhibitors of P450Arom, J. Pharm. Pharmacol. 50 (11) (1998) 1321-1330.
68. T.K. Vinh, M. Ahmadi, P.O. Delgado, S.F. Perez, H.M. Walters, H.J. Smith, P.J. Nicholls, C. Simons, 1-[(Benzofuran-2-yl)phenylmethyl]-triazoles and -tetrazoles - potent competitive inhibitors of aromatase, Bioorg. Med. Chem. Lett. 9 (14) (1999) 2105-2108.
69. J. Doiron, A.H. Soultan, R. Richard, M.M. Toure, N. Picot, R. Richard, M.C. Culf, G.A. Robichaud, M. Touaibia, Synthesis and structure activity relationship of 1-and 2-substituted-1,2,3-triazole letrozole-based analogues as aromatase inhibitors, Eur. J. Med. Chem. 46 (2011) 4010-4024.
70. R. Pingaew, V. Prchayasittikul, P. Mandi, C. Nantasenamat, S. Prachayasittikul, S. Ruchirawat, V. Prachayasittikul, Synthesis and molecular docking of 1,2,3-triazole-based sulfonamides as aromatase inhibitors, Bioorg. Med. Chem. 23 (13) (2015) 3472-3480.
71. M.G. Ferlin, D. Carta, R. Bortolozzi, R. Ghodsi, A. Chimento, V. Pezzi, S. Moro, N. Hanke, R.W. Hartmann, G. Basso, G. Viola, Design, synthesis and structure-activity relationship of azolylmethylpyrroloquinolines as nonsteroidal aromatase inhibitors, J. Med. Chem. 56 (2013) 7536-7551.
72. (a) R.W. Brueggemeier, J.C. Hackett, E.S. Diaz-Cruz, Aromatase inhibitors in the treatment of breast cancer, Endocr. Rev. 26 (3) (2005) 331-345;
73. (b) S. Mirzaie, L. Chupani, E.B. Asadabadi, A.R. Shahverdi, M. Jamalan, Novel inhibitor discovery against aromatase through virtual screening and molecular dynamic simulation: a computational approach drug design, EXCLI J. 12 (2013) 168-183.
74. M. Recanatini, A. Bisi, A. Cavalli, F. Belluti, S. Gobbi, A. Rampa, P. Valenti, M. Palzer, A. Palusczak, R.W. Hartmann, A new class of nonsteroidal aromatase Inhibitors: design and synthesis of chromone and xanthone derivatives and inhibition of the P450 enzymes aromatase and 17α-Hydroxylase/C17,20-Lyase, J. Med. Chem. 44 (5) (2001) 672-780.
75. Y.W. Kim, J.C. Hackett, R.W. Brueggemeier, Synthesis and aromatase inhibitory activity of novel pyridine containing isoflavones, J. Med. Chem. 47 (2004) 4032-4040.
76. J.C. Hackett, Y.W. Kim, B. Su, R.W. Brueggemeier, Synthesis and characterization of azole isoflavone inhibitors of aromatase, Bioorg. Med. Chem. 13 (2005) 4063-4070.
77. K. Bonfield, E. Amato, T. Bankemper, H. Agard, J. Steller, J.M. Keeler, D. Roy, A. McCallum, S. Paula, L. Ma, Development of a new class of aromatase inhibitors: design, synthesis and inhibitory activity of 3-phenylchroman-4-one (isoflavanone) derivatives, Bioorg. Med. Chem. 20 (8) (2012) 2603-2613.
78. E. Amato, T. Bankemper, R. Kidney, T. Do, A. Onate, F.S. Thowkeik, E.J. Merino, S. Paula, L. Ma, Investigation of fluorinated and bifunctionalized 3-phenylchroman-4-one (isoflavanone) aromatase inhibitors, Bioorg. Med. Chem. 22 (1) (2014) 126-134.
79. S. Yahiaoui, C. Pouget, C. Fagnere, Y. Champavier, G. Habrioux, A.J. Chulia, Synthesis and evaluation of 4-triazolylflavans as new aromatase inhibitors, Bioorg. Med. Chem. Lett. 14 (20) (2004) 5215-5218.
80. S. Yahiaoui, C. Fagnere, C. Pouget, J. Buxeraud, A.-J. Chulia, New 7,8-benzoflavanones as potent aromatase inhibitors: synthesis and biological evaluation, Bioorg. Med. Chem. 16 (2008) 1474-1480.
81. S. Luqman, A. Meena, P. Singh, T.P. Kondratyuk, L.E. Marler, J.M. Pezzuto, A.S. Negi, Neoflavonoids and tetrahydroquinolones as possible cancer chemopreventive agents, Chem. Biol. Drug Des. 80 (4) (2012) 616-624.
82. F. Leonetti, A. Favia, A. Rao, R. Aliano, A. Paluszcak, R.W. Hartmann, A. Carotti, Design, synthesis, and 3D QSAR of novel potent and selective aromatase inhibitors, J. Med. Chem. 47 (2004) 6792-6803.
83. A. Stefanachi, A.D. Favia, O. Nicolotti, F. Leonetti, L. Pisani, M. Catto, C. Zimmer, R.W. Hartmann, A. Carotti, Design, synthesis and biological evaluation of imidazolyl derivatives of 4,7-disubstituted coumarins as aromatase inhibitors selective over 17-α-hydroxylase/C17-20 lyase, J. Med. Chem. 54 (2011) 1613-1625.
84. B. Sun, J. Hoshino, K. Jermihov, L. Marler, J.M. Pezzuto, A.D. Mesecar, M. Cushman, Design, synthesis and biological evolution of resveratrol analogues as aromatase and quinone reductase 2 inhibitors for chemoprevention of cancer, Bioorg. Med. Chem. 18 (14) (2010) 5352-5366.
85. A.S. Mayhoub, L. Marler, T. Kondratyuk, E.-J. Park, J.M. Pezzuto, M. Cushman, Optimizing thiadiazole analogues of resveratrol vs. three chemopreventive targets, Bioorg. Med. Chem. 20 (1) (2012) 510-520.
86. J. Hoshino, E.J. Park, T.P. Kondratyuk, L. Marler, J.M. Pezzuto, R.B. van Breeman, S. Mo, Y. Li, M. Cushman, Selective synthesis and biological evaluation of sulfate-conjugated resveratrol metabolites, J. Med. Chem. 53 (13) (2010) 5033-5043.
87. W. Lv, J. Liu, D. Lu, D.A. Flockhart, M. Cushman, Synthesis of mixed (E,Z)-, (E)-, and (Z)-norendoxifen with dual aromatase inhibitory and estrogen receptor modulatory activities, J. Med. Chem. 56 (11) (2013) 4611-4618.
88. W. Lv, J. Liu, T.C. Skaar, D.A. Flockhart, M. Cushman, Design and synthesis of norendoxifen analogues with dual aromatase inhibitory and estrogen receptor modulatory activities, J. Med. Chem. 58 (2015) 2623-2648.
89. Y. Dai, Y. Xiao, Q. Wang, S. Wei, X. Zhang, Z. Ma, H. Zheng, M. Hou, T. Zhang, Synthesis and QSAR studies of benzylimidazole derivatives and benzylcarbazole as potential aromatase inhibitors, Asian J. Chem. 26 (8) (2014) 2381-2388.
90. L. Shen, E.-J. Park, T.P. Kondratyuk, D. Guendisch, L. Marler, J.M. Pezzuto, A.D. Wright, D. Sun, Design, synthesis and biological evaluation of callophycin A and analogues as potential chemopreventive anticancer agents, Bioorg. Med. Chem. 19 (21) (2011) 6182-6195.
91. V. Prachayasittikul, R. Pingaew, C. Nantasenamat, S. Prachayasittikul, S. Ruchirawat, V. Prachaysittikul, Investigation of aromatase inhibitory activity of metal complexes of 8-hydroxyquinoline and uracil derivatives, Drug Des. Dev. Ther. 8 (2014) 1089-1096.
92. P.M. Wood, L.W.L. Woo, M.P. Thomas, M.F. Mahon, A. Purohit, B.V.L. Potter, Aromatase and dual aromatase-steroid sulfatase inhibitors from the letrozole and vorozole templates, Chem. Med. Chem. 6 (2011) 1423-1438.
93. L.W.L. Woo, C. Bubert, A. Purohit, B.V.L. Potter, Hybrid dual aromatase steroid sulfatase inhibitors with exquisite picomolar inhibitory activity, ACS Med. Chem. Lett. 2 (2011) 243-247.
94. L.W.L. Woo, P.M. Wood, C. Bubert, M.P. Thomas, A. Purohit, B.V.L. Potter, Synthesis and structure-activity relationship studies of derivatives of the dual aromatase-sulfatase inhibitor 4-{[(4-cyanophenyl)(4H-1,2,4-triazol-4-yl) amino]methyl}phenyl sulfamate, Chem. Med. Chem. 8 (2013) 779-799.